Bloch Orin G, Jian Brian J, Yang Isaac, Han Seunggu J, Aranda Derick, Ahn Brian J, Parsa Andrew T
Department of Neurological Surgery, University of California at San Francisco, San Francisco, California.
Skull Base. 2010 May;20(3):149-56. doi: 10.1055/s-0029-1246218.
The literature regarding recurrences in patients with cranial chondrosarcoma is limited to small series performed at single institutions, raising the question if these data precisely reflect the true recurrence of this tumor for guiding the clinician in the management of these patients. An extensive systematic review of the English literature was performed. The patients were stratified according to treatment modality, treatment history, histological subtype, and histological grade, and the recurrence rates were analyzed. A total of 560 patients treated for cranial chondrosarcoma were included. Five-year recurrence rate among all patients was 22% with median follow-up of 60 months and median disease-free interval of 16 months. Tumor recurrence was more common in patients who only received surgery or had mesenchymal subtype tumors. Our systematic review closely reflects the actuarial recurrence rate and provides predictive factors in the recurrence of cranial chondrosarcoma.
关于颅底软骨肉瘤患者复发情况的文献仅限于单个机构开展的小样本研究系列，这就引发了一个问题，即这些数据是否能准确反映该肿瘤的真实复发情况，从而为临床医生管理这些患者提供指导。我们对英文文献进行了广泛的系统综述。根据治疗方式、治疗史、组织学亚型和组织学分级对患者进行分层，并分析复发率。总共纳入了560例接受颅底软骨肉瘤治疗的患者。所有患者的5年复发率为22%，中位随访时间为60个月，中位无病间期为16个月。肿瘤复发在仅接受手术治疗的患者或具有间充质亚型肿瘤的患者中更为常见。我们的系统综述密切反映了实际复发率，并提供了颅底软骨肉瘤复发的预测因素。
